top of page
The Opportunity
Together We Conquer Breast Cancer
"There is no 1st, 2nd or 3rd place, when we capitalize on our strengths, work together and encourage each other forward. We ALL succeed.
THE PATIENT IS THE ULTIMATE WINNER." ~ Terry M. Ryusaki
Chief Commercial Officer
Play Video
The presumptive Triple Negative BC diagnosis, ruling out ER+, PR+, and Her2+ tumors, has been an inadequate and inaccurate surrogate for BLBC.
Recent genomic studies demonstrate the presence of the basal - like subtype in ER+ and Her2+ tumors.*
Advanced genomics research at the turn of the century led to the discovery of the basal - like molecular subtype.
While you were reading this, another child lost her mother somewhere in the world.
Millions of breast cancer survivors in remission may not have received effective chemotherapy to destroy the previously undetectable BLBC.
* 20% - 30% of BLBC tumors expressed estrogen and Her2 receptors.
AVISI0™ FOXC1 IHC is the first IVD test designed to assist pathologists in the diagnosis of BLBC.
AVISI0™ FOXC1 ImmunoHistoChemistry
-
FOXC1 has been identified as a specific biomarker for BLBC in general breast cancer cohorts.
-
Designed to aid in the diagnosis of BLBC, basal - luminal and basal - HER2 in FFPE breast carcinoma tissue.
-
Excellent specificity, sensitivity, positive predictive value, negative predictive value and concordance.
-
Easy to read nuclear staining using standard light microscopy.
-
Not found in nucleus of normal breast tissue.
-
Brings specialized genomics research results into every clinical laboratory using established IHC technology.
-
Optimized to seamlessly integrate into the routine laboratory workflow using existing equipment.
-
AVISI0™ FOXC1 IHC complies with all applicable European Union in vitro diagnostic medical device directives and has secured CE marking for commercial sales in the European Union.
-
Protocols developed for existing automated immunohistochemisty systems. *
* Alliance established with automated IHC system to support optimization and customer (ready-to-use) convenience.
The Product
Patents
Intellectual Property
26 PATENTS
ISSUED
WORLDWIDE
Why reinvent the wheel by spending significant dollars, while diverting valuable resources on a high risk projects with uncertain outcomes?
Three families of patents covering the AVISI0™ technology
The only one who wins in patent litigation are the lawyers. Why take the risk? We are currently approaching market leaders with mutually beneficial opportunities.
Intellectual property
Trademarks, R&D
Territory: The Americas,
Far East and ROW
Onconostic Technologies, Inc., a Delaware corporation, and its EU affliate 3N Diagnostics, a Belfast, Northern Ireland company, together owns all of the rights to AVISI0™ FOXC1.
Manufacturing, QA, QC
Territory: European Union and ROW
AFFILIATED COMPANIES IN THE US AND UK
ABOUT US
 |  |  |
|---|---|---|
 |  |  |
 |
MEET THE TEAM
About Us
Complete Interview with Founder
Partha S. Ray, MD
Founder, Director, Chairman-Medical Advisiory Board
Interview
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. AVISIO™ products are not available in the United States of America and this website is not intended for viewing by US residents.
Video Channel Name
bottom of page